Results 211 to 220 of about 169,700 (260)
Some of the next articles are maybe not open access.
Immunomodulatory therapy for sepsis: an update
Expert Review of Anti-infective Therapy, 2011Currently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support each failing organ. Activated protein C and hydrocortisone, when used accordingly can affect mortality.
Christaki, Eirini +5 more
openaire +3 more sources
Immunomodulatory therapy for severe influenza
Expert Review of Anti-infective Therapy, 2011Influenza A virus is a significant cause of morbidity and mortality worldwide. Severe influenza is recognized as a clinical syndrome, characterized by hyperinduction of proinflammatory cytokine production, otherwise known as hypercytokinemia or a 'cytokine storm'.
Ilyse, Darwish +2 more
openaire +2 more sources
Immunomodulatory Therapy in Uveitis
2015Corticosteroids are the cornerstone of treating intraocular inflammation, but may be inadequate in controlling the disease, or related side effects preclude long-term treatment. Additional immunosuppressive drugs are used in these cases to augment the effect of corticosteroids and allow for their reduction to safe levels while maintaining control of ...
Oren, Tomkins-Netzer +4 more
openaire +2 more sources
Immunomodulatory aspects of photodynamic therapy
Expert Opinion on Investigational Drugs, 1998In its conventional form, photodynamic therapy (PDT) is a clinically effective technique with which to treat tumours accessible to visible light. PDT utilises light absorbing compounds which catalyse the generation of toxic oxygen species, to produce localised antitumour effects.
D W, Hunt, J G, Levy
openaire +2 more sources
Immunomodulatory therapy in yeast infections
Expert Review of Anti-infective Therapy, 2007Invasive yeast infections are a significant cause of morbidity and mortality in patients with defective immune response, such as those with cancer-related immunosuppression, organ transplantation or other immunodeficiencies, and neonates. Hospitalization in the intensive care unit may increase the risk for such infections.
Garbino J, Katragkou A, Roilides E
openaire +3 more sources
Immunomodulatory gene therapy for haematological malignancies [PDF]
British Journal of Haematology, 2002 G D, Schmidt-Wolf, I G H, Schmidt-Wolf
exaly +3 more sources
Immunomodulatory Therapy for Myelodysplastic Syndromes
International Journal of Hematology, 2007Thalidomide and lenalidomide belong to the proprietary group of immunomodulatory drugs (IMiDs) that display broad biologic and pharmacologic properties. Encouraging results of clinical studies that evaluated the efficacy of thalidomide in patients with myelodysplastic syndromes (MDSs) led to the investigation of its structural analogue, lenalidomide ...
Lubomir, Sokol, Alan F, List
openaire +2 more sources
Veterinary Dermatology, 2004
In veterinary dermatology, the therapeutic approach to numerous diseases (e.g. hypersensitivity and autoimmunity) centres upon suppression of an overactive immune system. By contrast, in other situations such as infectious diseases and cancer, it may be desirable to enhance an ineffective immune response.
openaire +1 more source
In veterinary dermatology, the therapeutic approach to numerous diseases (e.g. hypersensitivity and autoimmunity) centres upon suppression of an overactive immune system. By contrast, in other situations such as infectious diseases and cancer, it may be desirable to enhance an ineffective immune response.
openaire +1 more source
Immunomodulatory effects of targeted radionuclide therapy
2023It is now clear that conventional radiation therapy can reinstate cell death immunogenicity. Recent preclinical data indicate that targeted radionuclide therapy that irradiate tumors at continuous low dose rate also can elicit immunostimulatory effects and represents a promising strategy to circumvent immune checkpoint inhibitor resistance.
Constanzo, J. +5 more
openaire +2 more sources
Immunomodulatory Drugs as a Therapy for Multiple Myeloma
Current Pharmaceutical Biotechnology, 2006Thalidomide and the analogues lenalidomide (CC-5013, Revlimid) and CC-4047 (Actimid) belong to the family of immunomodulatory drugs (IMiDs). These agents have anti-angiogenic properties, modulate TNFalpha and IL-12 secretion, co-stimulate T cells, increase NK cell toxicity and have direct anti-tumour effects.
De Raeve, Hendrik, Vanderkerken, Karin
openaire +4 more sources